BioCurex, Inc.(fka BOCX)

[cannonball2010]

smallcap network comments about thereport


BioCurex - The Word is Out.


SmallCap Digest is pleased to make available --to current as well as new subscribers-- an extremely detailed 24-page research report on the current and future prospects for one of our favorite biotech companies, BioCurex Inc (BOCX.PK).
To acquire your online copy in PDF format simply click the following link or copy and paste it in your browser: http://www.smallcapdigest.net/news_images/bocx_research_report.pdf.

Get all the facts and more…

This exhaustive report, written by Emergent Growth Analytics Director of Research Justin Frere (MBA, CPA) is de rigueur for those serious investors interested in both the amazing potential of BioCurex as well as the smallcap biotech market.

The report clearly defines BioCurex’s present market opportunities to which Mr. Frere assigns a price target/value of $2.17—representing roughly a100 percent return from recent share price levels.

More importantly, the report states:

“Our valuation does not include the potential significant revenues that might be generated if BioCurex and their licensee successfully complete immunotherapy based applications that target specific tumors and effectively immunize against or destroy cancer”.

While SmallCap Digest always brings you timely and actionable trading information, a detailed report such as this gives investors the luxury of seeing all the historical data as well as the potential for this unique and exciting company. Charts and graphics as well as comparables with more than a dozen other biotechs are included as are the hard corporate numbers.

All in all, whether you are a long-term shareholder, just coming to BioCurex, or want a definitive assessment of the company, this report is a definite ‘ must read’.

The report, while detailing BioCurex’s current RECAF™ product platform, also delineates the potential of the company’s future systemic applications such as imaging and vaccines:

“Initial systemic product candidates will most likely be targeted at the most prolific cancer types including prostate, cervical, breast, lung, colon, etc., in which treatments, cures, and diagnostics are in great demand. Accordingly, these potential product applications could represent an even greater revenue and profit opportunity for BioCurex than its diagnostic and testing applications”.

The report also discusses BioCurex’s recent semi-exclusive licensing arrangement with Abbott Labs (NYSE: ABT). The research gives opinion on both the validation gained by BOCX and the potential incorporation of its technology into Abbott’s suite of high-volume diagnostic tests:

“Recently, Abbott Laboratories licensed certain aspects of BioCurex’s serum assay technology on a semi-exclusive worldwide basis after conducting thorough testing. Abbott’s belief that RECAF™ could provide good clinical sensitivity and specificity as a tumor marker is a substantial validation of BioCurex’s technology, and we expect to see Abbott further develop the technology and incorporate it into further tests on its ARCHITECT® system for use in cancer diagnosis and monitoring”.

All in all a virtual plethora of great information. Click the link above and access your copy.

We feel that this report strongly reinforces our contention—which we first alerted the readership to in October 2003 when BioCurex was at 17 cents—that the technology and potential for the company remains extremely compelling.

As we have oft-said, the shares deserve a position in the biotech section of your portfolio for what we believe will be superior long-term gains. We’re confident that you’ll find both this report and our continued coverage of BioCurex extremely helpful in that regard.

The BioCurex press release regarding the release of the report may be viewed here:
http://biz.yahoo.com/pz/050722/82606.html